Matteo Repetto

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity”.

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

Cancers(2023)10.3390/cancers15164146

N/A

0DataRank · unranked

43 citations

Matteo Repetto, Soo‐Ryum Yang, Eric J. Sherman, Alexander Drilon, Antoine Desîlets

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

Drugs(2024)10.1007/s40265-024-02040-5

N/A

0DataRank · unranked

17 citations

Matteo Repetto, Clare Wilhelm, Alexander Drilon, Monica F. Chen

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

British Journal of Cancer(2024)10.1038/s41416-024-02760-1

N/A

0DataRank · unranked

13 citations

Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina +17 more